The European Medicines Agency’s Committee for Orphan Medicinal Products has issued a positive opinion on the orphan drug designation for RZ-001, a gene therapy developed by South Korean firm Rznomics to treat glioma. The decision follows clinical data suggesting the treatment offers significant benefits for patients facing recurrent glioblastoma.
RZ-001, or taspitimagene advec, operates on a proprietary RNA trans-splicing ribozyme platform. It targets hTERT mRNA, which is overexpressed in the vast majority of human cancers, replacing it with a therapeutic sequence that encodes the herpes simplex virus thymidine kinase. This process triggers selective apoptosis in malignant cells, a mechanism that has shown promise in ongoing Phase 1/2a trials.
For patients with recurrent glioblastoma, a Grade IV brain cancer with a one-year survival rate below 25%, the designation marks a critical regulatory milestone. Beyond clinical validation, the status grants Rznomics access to significant commercial incentives, including up to a decade of market exclusivity in Europe and reduced regulatory filing fees.
Company leadership emphasized that the recommendation validates the broader potential of their RNA editing technology. Following a previous RMAT designation from the FDA for hepatocellular carcinoma, the firm is now looking to accelerate global development and expand the therapy's target indications. Currently, the treatment has been administered to 10 clinical trial participants and 3 patients under the U.S. FDA's Expanded Access Program.
Comments (0)
No comments yet. Be the first!